Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.
Saved in:
| Title: | Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease. |
|---|---|
| Authors: | Burton J; Biogen Inc., Cambridge, MA, USA. Electronic address: Jackson.Burton@Biogen.com., Brothers HM; Biogen Inc., Cambridge, MA, USA., Hutchison RM; Biogen Inc., Cambridge, MA, USA., Murphy J; Biogen Inc., Cambridge, MA, USA., Sun T; Biogen Inc., Cambridge, MA, USA., Dent G; Biogen Inc., Cambridge, MA, USA., Curiale G; Biogen Inc., Cambridge, MA, USA., Kowalski K; Kowalski PMetrics Consulting, LLC, Naples, FL, USA. |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Aug; Vol. 12 (7), pp. 100202. Date of Electronic Publication: 2025 May 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
